Phospho-MDM2 (Ser186/Ser188) Antibody

What is the specificity of the Phospho-MDM2 (Ser186/S188) antibody?

The Phospho-MDM2 (Ser186/S188) polyclonal antibody demonstrates high specificity, detecting endogenous levels of MDM2 protein exclusively when phosphorylated at the Ser186 and Ser188 residues . This specificity is achieved through careful immunogen design, with the antiserum produced against a synthesized peptide derived from human MDM2 encompassing the amino acid range 151-200, specifically targeting the region around the phosphorylation sites Ser186 and Ser188 . The antibody has been validated through Enzyme-Linked Immunosorbent Assay (Phospho-ELISA) comparing immunogen phosphopeptide and non-phosphopeptide reactions . This high specificity makes it particularly valuable for distinguishing phosphorylated MDM2 from its non-phosphorylated form in experimental settings examining post-translational regulation of this important oncoprotein.

What are the recommended applications for Phospho-MDM2 (Ser186/S188) antibody?

The Phospho-MDM2 (Ser186/S188) antibody has been extensively validated for multiple research applications with specific optimal dilution ranges for each technique. For Western Blot (WB) analysis, the recommended dilution range is 1:500-2000, allowing researchers to detect phosphorylated MDM2 in protein lysates with high sensitivity . For Immunofluorescence (IF) applications, the optimal dilution range is 1:200-1:1000, enabling visualization of subcellular localization patterns of phosphorylated MDM2 . For ELISA-based quantification methods, the antibody performs best at higher dilutions of 1:20000 . These applications enable comprehensive analysis of phosphorylated MDM2 expression, localization, and quantification in various experimental models, providing researchers flexibility in experimental design depending on their specific research questions.

How should the Phospho-MDM2 (Ser186/S188) antibody be stored to maintain optimal activity?

For optimal preservation of antibody activity, the Phospho-MDM2 (Ser186/S188) antibody should be stored at -20°C for up to one year from the date of receipt . The antibody is supplied in a stabilizing solution of PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps maintain protein integrity during storage . To prevent activity loss, it is crucial to avoid repeated freeze-thaw cycles, which can lead to protein denaturation and diminished antibody performance . For laboratories conducting ongoing experiments, it is advisable to prepare small working aliquots upon receipt to minimize freeze-thaw events. When handling the antibody during experimentation, it should be kept on ice or at 4°C for short-term use, and returned to -20°C promptly after use to maximize shelf-life and maintain consistent experimental results across studies.

What is the functional significance of MDM2 phosphorylation at Ser186/S188?

The phosphorylation of MDM2 at Ser186/S188 represents a critical post-translational modification that significantly impacts MDM2's function in the p53 regulatory pathway. While the search results don't specifically detail the consequences of phosphorylation at these exact residues, contextual information about MDM2 phosphorylation indicates its importance in regulating protein function . MDM2, as an E3 ubiquitin-protein ligase, mediates ubiquitination of p53/TP53, leading to p53 degradation by the proteasome . Phosphorylation at various sites, including Ser186/S188, likely modulates this activity. By comparison, phosphorylation at a different site (Ser166) has been linked to increased MDM2 stability and enhanced p53 degradation . The phosphorylation status of MDM2 represents a key regulatory mechanism in cancer biology, as MDM2 functions as an oncogenic protein by suppressing the tumor suppressor activities of p53. Understanding the specific effects of Ser186/S188 phosphorylation provides insights into potential therapeutic targets for restoring p53 function in cancer treatment strategies.

How does phosphorylation at Ser186/S188 differ from other MDM2 phosphorylation sites in terms of downstream effects?

The phosphorylation landscape of MDM2 is complex, with multiple phosphorylation sites mediating distinct functional outcomes in the p53 regulatory pathway. Phosphorylation at Ser186/S188 must be considered within this broader context. From the search results, we know that phosphorylation at Ser166 by SGK1 activates ubiquitination of p53/TP53 , promoting p53 degradation and inhibiting its tumor suppressor function. In contrast, phosphorylation near the RING domain by ATM upon DNA damage prevents oligomerization and E3 ligase processivity, thereby impeding constitutive p53/TP53 degradation . This suggests different phosphorylation sites can have opposing effects on MDM2's ability to regulate p53.

While the exact downstream effects of Ser186/S188 phosphorylation aren't explicitly detailed in the search results, the development of specific antibodies targeting these sites suggests their biological significance. For comprehensive investigation, researchers should consider employing multiple phospho-specific antibodies (including those targeting Ser166, Ser186/S188, and sites phosphorylated by ATM) to map the complete phosphorylation status of MDM2 under various cellular conditions and stress responses. This multi-site phosphorylation analysis would reveal potential synergistic or antagonistic relationships between different phosphorylation events on MDM2 function.

What controls should be included when validating the specificity of Phospho-MDM2 (Ser186/S188) antibody in experimental setups?

Rigorous validation of phospho-specific antibodies requires a comprehensive set of controls to ensure experimental reliability and specificity. For Phospho-MDM2 (Ser186/S188) antibody, the following validation controls are essential:

• Blocking peptide control: The search results indicate immunofluorescence analysis using this antibody should include controls where the antibody is pre-incubated with the phospho-peptide used as immunogen . This competition assay should eliminate specific signal, confirming antibody specificity.

• Phosphatase treatment control: Samples should be split and one portion treated with lambda phosphatase to remove phosphate groups. The phospho-specific antibody should show diminished or absent signal in the phosphatase-treated samples.

• Genetic controls: Using MDM2 knockout or knockdown cell lines, or cells expressing MDM2 with Ser186/S188 to Alanine mutations to confirm signal specificity.

• Physiological modulators: Treatment with agents known to affect MDM2 phosphorylation status, such as DNA damaging agents that activate ATM , should produce predictable changes in Ser186/S188 phosphorylation.

• Cross-reactivity testing: Testing the antibody against related phosphorylation sites (like Ser166) to ensure it doesn't cross-react with other phosphorylated residues on MDM2.

Implementing these controls ensures that experimental observations truly reflect the phosphorylation status of MDM2 at Ser186/S188, rather than non-specific binding or artifacts.

How does the subcellular localization of phosphorylated MDM2 (Ser186/S188) compare to non-phosphorylated MDM2?

The subcellular localization of MDM2 is a critical aspect of its function in regulating p53 and other target proteins. According to the search results, MDM2 is expressed predominantly in the nucleoplasm but can also be found in the nucleus, cytoplasm, and nucleolus under different conditions . The interaction with ARF(p14) results in the localization of both proteins to the nucleolus, with nucleolar localization signals in both proteins being necessary for efficient nucleolar localization .

To determine if phosphorylation at Ser186/S188 affects this subcellular distribution pattern, researchers should conduct co-localization experiments using:

• Dual immunofluorescence with both phospho-specific (Ser186/S188) and total MDM2 antibodies

• Cell fractionation followed by Western blotting to quantify relative distribution across cellular compartments

• Time-course analysis following stimuli that induce MDM2 phosphorylation

Such experiments would reveal whether Ser186/S188 phosphorylation alters the nuclear-cytoplasmic shuttling of MDM2, affects its nucleolar localization, or influences its co-localization with key binding partners like p53 or ARF. Given that MDM2 permits the nuclear export of p53/TP53 , understanding how Ser186/S188 phosphorylation might modulate this function could provide insights into p53 regulation under normal and stress conditions.

What is the relationship between MDM2 phosphorylation at Ser186/S188 and its autoubiquitination activity?

The relationship between MDM2 phosphorylation at Ser186/S188 and its autoubiquitination activity represents a complex regulatory mechanism affecting MDM2 stability and function. From the search results, we know that MDM2 undergoes autoubiquitination leading to its proteasomal degradation, which results in p53/TP53 activation . This process may be regulated by Stratifin (SFN) . Additionally, MDM2 is also ubiquitinated by TRIM13 and can be deubiquitinated by USP2 (leading to MDM2 accumulation and increased p53 degradation) or USP7 (leading to MDM2 stabilization) .

To investigate the specific impact of Ser186/S188 phosphorylation on autoubiquitination activity, researchers should consider:

• Comparing ubiquitination patterns of wild-type MDM2 versus phospho-mimetic (S186E/S188E) and phospho-deficient (S186A/S188A) mutants

• Assessing MDM2 half-life in conditions promoting or inhibiting Ser186/S188 phosphorylation

• Examining interactions between phosphorylated MDM2 (Ser186/S188) and deubiquitinating enzymes like USP2 and USP7

These experiments would determine whether Ser186/S188 phosphorylation enhances or inhibits MDM2 autoubiquitination, thereby affecting MDM2 stability and consequently its regulation of p53 and other target proteins in the cell.

What are the optimal sample preparation conditions for detecting phospho-MDM2 (Ser186/S188) in various experimental systems?

Detecting phosphorylated proteins requires careful sample preparation to preserve phosphorylation status throughout the experimental workflow. For optimal detection of phospho-MDM2 (Ser186/S188), the following methodological considerations are critical:

Table 1: Sample Preparation Recommendations for Phospho-MDM2 (Ser186/S188) Detection

When working with cell culture systems, stimulation conditions that activate relevant signaling pathways should be carefully optimized. Since MDM2 is phosphorylated at multiple sites near the RING domain by ATM upon DNA damage , researchers might consider treatment with DNA-damaging agents like etoposide or doxorubicin to increase phosphorylation at specific sites for positive controls. Rapid sample processing is essential as phosphatases remain active even at low temperatures, potentially reducing detectable phosphorylation signals. The dilution ranges specified for the phospho-MDM2 (Ser186/S188) antibody (WB 1:500-2000, IF 1:200-1:1000, ELISA 1:20000) should be optimized for each experimental system to achieve optimal signal-to-noise ratio.

How can researchers troubleshoot weak or absent phospho-MDM2 (Ser186/S188) signal in Western blot applications?

Detecting phosphorylated proteins by Western blot can be challenging due to their often low abundance and sensitivity to sample processing. When troubleshooting weak or absent phospho-MDM2 (Ser186/S188) signals, consider the following systematic approach:

Table 2: Troubleshooting Guide for Weak Phospho-MDM2 (Ser186/S188) Western Blot Signals

What are the best strategies for multiplex detection of different MDM2 phosphorylation sites in the same sample?

Analyzing multiple phosphorylation sites on MDM2 simultaneously provides valuable insights into the complex regulation of this protein under various cellular conditions. Given MDM2's multiple phosphorylation sites, including Ser166, Ser186/S188, and those phosphorylated by ATM near the RING domain , developing effective multiplex detection strategies is crucial for comprehensive analysis.

Table 3: Strategies for Multiplex Detection of MDM2 Phosphorylation Sites

When designing multiplex experiments, consider the phospho-MDM2 (Ser186/S188) antibody characteristics: it's a rabbit polyclonal antibody that detects endogenous levels of MDM2 protein only when phosphorylated at S186/S188 . This should be paired with antibodies raised in different host species (e.g., mouse, goat) targeting other phosphorylation sites to enable simultaneous detection. The relationship between different phosphorylation events on MDM2 can provide crucial insights into how this protein integrates various signaling inputs to regulate p53 and other downstream targets in normal and cancer cells.

How can researchers quantitatively assess changes in MDM2 Ser186/S188 phosphorylation in response to cellular stress?

Quantitative assessment of changes in MDM2 phosphorylation at Ser186/S188 following cellular stress requires careful experimental design and appropriate analytical methods. Based on the known biology of MDM2, including its phosphorylation by ATM upon DNA damage , researchers can implement the following approaches:

Table 4: Quantitative Methods for Assessing MDM2 Ser186/S188 Phosphorylation Changes

For stress response experiments, consider the following stimuli known to affect MDM2 phosphorylation:

• DNA damage inducers (e.g., etoposide, doxorubicin, ionizing radiation)

• Proteasome inhibitors (e.g., MG132) to prevent degradation of phosphorylated MDM2

• Specific kinase activators or inhibitors relevant to MDM2 regulation

Time-course experiments are particularly valuable, as phosphorylation events are often dynamic. Using the optimal dilutions recommended for the phospho-MDM2 (Ser186/S188) antibody (WB 1:500-2000, IF 1:200-1:1000, ELISA 1:20000) , researchers can reliably detect and quantify changes in MDM2 phosphorylation status in response to various cellular stresses, providing insights into the regulation of this critical oncogenic protein.

How can Phospho-MDM2 (Ser186/S188) antibody be used to evaluate the efficacy of MDM2-targeting cancer therapeutics?

MDM2 is a promising target for cancer therapeutics due to its role as an oncoprotein that negatively regulates the tumor suppressor p53 . The phosphorylation status of MDM2 at Ser186/S188 could serve as a valuable biomarker for assessing the efficacy of MDM2-targeting therapeutics. Researchers can implement several methodological approaches using the phospho-MDM2 (Ser186/S188) antibody:

• Target engagement studies: Evaluating whether small molecule MDM2 inhibitors affect the phosphorylation status at Ser186/S188, which could indicate altered MDM2 conformation or kinase accessibility.

• Pharmacodynamic biomarker development: Monitoring changes in MDM2 Ser186/S188 phosphorylation in patient-derived xenografts or clinical samples before and after treatment with MDM2 inhibitors.

• Resistance mechanism investigations: Comparing Ser186/S188 phosphorylation patterns between treatment-responsive and treatment-resistant tumors to identify potential phosphorylation-dependent escape mechanisms.

• Combination therapy rationale: Using phosphorylation status to guide the selection of kinase inhibitors that might synergize with direct MDM2 antagonists by preventing activating phosphorylation events.

Given that MDM2 functions as an E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53 leading to its degradation , therapeutic strategies that disrupt this function are of particular interest. The phospho-MDM2 (Ser186/S188) antibody, with its high specificity for detecting endogenous levels of MDM2 protein only when phosphorylated at S186/S188 , provides a powerful tool for evaluating how novel therapeutics affect this critical post-translational modification and its downstream consequences on MDM2-p53 pathway regulation.

What insights can phosphorylation analysis of MDM2 provide about cross-talk between DNA damage and growth factor signaling pathways?

MDM2 serves as a critical integration point between DNA damage response and growth factor signaling pathways, with its phosphorylation status reflecting the balance of these inputs. The search results indicate that MDM2 is a component of the TRIM28/KAP1-MDM2-p53/TP53 complex involved in stabilizing p53/TP53, as well as the TRIM28/KAP1-ERBB4-MDM2 complex which links growth factor and DNA damage response pathways . The phosphorylation of MDM2 at various sites, including Ser186/S188, likely plays a role in regulating these complex interactions.

To investigate this cross-talk using the phospho-MDM2 (Ser186/S188) antibody, researchers could:

• Perform simultaneous treatment with DNA damaging agents and growth factors, followed by assessment of Ser186/S188 phosphorylation status.

• Analyze the temporal dynamics of MDM2 phosphorylation at Ser186/S188 compared to other phosphorylation sites (e.g., ATM-mediated phosphorylation near the RING domain) after sequential exposure to growth factors and DNA damage.

• Use phosphomimetic and phosphodeficient MDM2 mutants at Ser186/S188 to assess how this specific phosphorylation affects MDM2's ability to form complexes with TRIM28/KAP1, ERBB4, and p53 under various cellular conditions.

• Employ the antibody in chromatin immunoprecipitation (ChIP) experiments to determine if Ser186/S188 phosphorylation affects MDM2's association with p53 at target gene promoters.

How does the phosphorylation pattern of MDM2 at Ser186/S188 compare across different cancer types and stages?

Understanding the phosphorylation pattern of MDM2 at Ser186/S188 across different cancer types and stages could provide valuable insights into its role in oncogenesis and potential as a diagnostic or prognostic biomarker. While the search results don't provide specific data on this comparison, the phospho-MDM2 (Ser186/S188) antibody provides a tool for such investigations.

To comprehensively analyze this pattern, researchers should consider:

Table 5: Methodological Approach for Cancer-Type Comparative Analysis

Given MDM2's role as an oncoprotein that negatively regulates the tumor suppressor p53 , variation in its phosphorylation status at Ser186/S188 across cancer types might correlate with p53 pathway activity, treatment response, or clinical outcomes. The phospho-specific antibody that detects endogenous levels of MDM2 protein only when phosphorylated at S186/S188 enables precise quantification of this specific post-translational modification, potentially revealing cancer subtypes where this phosphorylation event plays a particularly important role in disease progression or treatment resistance.

How can the Phospho-MDM2 (Ser186/S188) antibody be used in conjunction with genetic approaches to study MDM2 function?

Integrating antibody-based detection with genetic manipulation provides powerful insights into protein function and regulation. For studying MDM2 phosphorylation at Ser186/S188, several complementary genetic approaches can be combined with antibody-based detection:

• CRISPR/Cas9-mediated genomic editing:

  • Generate MDM2 Ser186/Ser188 to Alanine (phospho-deficient) or Glutamic acid (phospho-mimetic) knock-in cell lines

  • Validate phenotypes using the phospho-MDM2 (Ser186/S188) antibody to confirm loss or constitutive detection of the phosphorylation signal

  • Assess functional consequences on p53 stability, transcriptional activity, and cellular responses to stress

• Conditional expression systems:

  • Develop tetracycline-inducible expression of wild-type versus mutant MDM2 (S186A/S188A or S186E/S188E) in MDM2-knockout backgrounds

  • Use the phospho-specific antibody to monitor endogenous versus exogenous protein phosphorylation

  • Study temporal dynamics of MDM2 function as related to its phosphorylation status

• Kinase identification approaches:

  • Employ siRNA/shRNA libraries targeting the kinome to identify kinases responsible for Ser186/S188 phosphorylation

  • Validate candidates using the phospho-specific antibody to detect reduced phosphorylation upon kinase knockdown

  • Confirm direct phosphorylation using in vitro kinase assays with recombinant proteins

The phospho-MDM2 (Ser186/S188) antibody, which specifically detects endogenous levels of MDM2 protein only when phosphorylated at S186/S188 , serves as an essential tool for validating genetic manipulations and quantifying their effects on MDM2 phosphorylation status. This integrated approach allows researchers to establish causative relationships between specific phosphorylation events and MDM2's various functions in regulating p53 and other target proteins.

What are the best approaches for integrating phospho-MDM2 (Ser186/S188) analysis with global phospho-proteomics studies?

Integrating targeted analysis of MDM2 phosphorylation at Ser186/S188 with global phospho-proteomics provides a comprehensive view of signaling networks and contextualizes MDM2 regulation within broader cellular pathways. Researchers can employ several strategies to achieve this integration:

Table 6: Integration of Targeted and Global Phosphorylation Analysis

When designing such integrated studies, researchers should consider that the phospho-MDM2 (Ser186/S188) antibody detects endogenous levels of MDM2 protein only when phosphorylated at S186/S188 , making it ideal for confirming mass spectrometry findings. The antibody can also be used for enrichment strategies prior to mass spectrometry analysis, potentially identifying proteins that specifically interact with MDM2 when phosphorylated at these residues. This integration allows researchers to place MDM2 phosphorylation events within the context of broader signaling networks, particularly those involved in cancer development and response to therapeutic interventions.

What emerging technologies might enhance the study of MDM2 phosphorylation dynamics in the future?

The field of protein post-translational modification analysis is rapidly evolving, with several emerging technologies poised to revolutionize our understanding of MDM2 phosphorylation dynamics. Future studies of MDM2 phosphorylation at Ser186/S188 will likely benefit from these technological advances:

• Live-cell phosphorylation sensors: Development of FRET-based or split fluorescent protein biosensors specifically designed to monitor MDM2 Ser186/S188 phosphorylation in real-time in living cells, enabling dynamic visualization of phosphorylation events in response to various stimuli.

• Single-cell phospho-proteomics: Advances in mass spectrometry sensitivity allow phosphorylation analysis at the single-cell level, potentially revealing heterogeneity in MDM2 phosphorylation status within tumors or during developmental processes.

• Spatial proteomics: Techniques like CODEX (CO-Detection by indEXing) or Multiplexed Ion Beam Imaging (MIBI) can map the spatial distribution of phosphorylated MDM2 within tissues while simultaneously detecting dozens of other proteins and phosphorylation sites.

• Nanobody-based detection: Development of nanobodies specifically recognizing MDM2 phosphorylated at Ser186/S188 could enable super-resolution microscopy applications and potentially intracellular tracking in living cells.

• Cryo-EM structural analysis: Structural determination of phosphorylated versus non-phosphorylated MDM2 could reveal how Ser186/S188 phosphorylation alters protein conformation and interactions with binding partners.

These technologies, combined with the continued use of well-validated antibody tools like the phospho-MDM2 (Ser186/S188) antibody , will provide increasingly detailed insights into the role of this post-translational modification in regulating MDM2 function in both normal cellular processes and disease states. The ultimate goal is to leverage this knowledge for the development of more effective and targeted cancer therapeutics that modulate the MDM2-p53 pathway.

How might understanding MDM2 phosphorylation contribute to personalized cancer treatment approaches?

Understanding the phosphorylation status of MDM2 at Ser186/S188 and other sites represents a promising avenue for advancing personalized cancer treatment strategies. MDM2 functions as an oncoprotein by negatively regulating the tumor suppressor p53 , and its phosphorylation status may serve as both a biomarker and a therapeutic target. Several potential applications in personalized medicine include:

• Predictive biomarker development: The phosphorylation pattern of MDM2 at Ser186/S188 could predict response to MDM2 inhibitors or p53-activating therapies, allowing patient stratification based on phosphorylation status.

• Combination therapy design: Understanding the kinases responsible for MDM2 phosphorylation at Ser186/S188 could guide rational combination of kinase inhibitors with MDM2 antagonists for synergistic effects in tumors where this phosphorylation promotes cancer progression.

• Resistance mechanism identification: Monitoring changes in MDM2 phosphorylation during treatment could reveal adaptive resistance mechanisms, enabling timely intervention with alternative strategies.

• Novel drug target identification: The protein-protein interactions specifically mediated by phosphorylated MDM2 might represent novel druggable targets for cancers where traditional MDM2 inhibition is ineffective.

• Patient monitoring: Liquid biopsy approaches detecting phosphorylated MDM2 could provide non-invasive means of tracking treatment efficacy and disease progression.